1-chloro-3-(3-methoxyphenylamino)-2-methylpropan-2-ol | 1260172-36-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-chloro-3-(3-methoxyphenylamino)-2-methylpropan-2-ol
• 英文别名: 1-Chloro-3-(3-methoxyanilino)-2-methylpropan-2-ol
• CAS: 1260172-36-8
• 化学式: C₁₁H₁₆ClNO₂
• 分子量: 229.707
• InChiKey: PONKTVHTZIDZMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-chloro-3-(3-methoxyphenylamino)-2-methylpropan-2-ol 在 potassium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 3-methoxy-N-((2-methyloxiran-2-yl)methyl)aniline
  参考文献：
  名称：

  Pro-neurogenic compounds

  摘要：

  这项发明通常涉及刺激神经发生（例如，后生神经发生，例如，后生海马神经发生）并保护免受神经细胞死亡的影响。

  公开号：

  US09095571B2
• 作为产物：
  描述：

  甲基环氧氯丙烷 、 间氨基苯甲醚 在 溶剂黄146 作用下， 以89%的产率得到1-chloro-3-(3-methoxyphenylamino)-2-methylpropan-2-ol
  参考文献：
  名称：

  Pro-neurogenic compounds

  摘要：

  这项发明通常涉及刺激神经发生（例如，后生神经发生，例如，后生海马神经发生）并保护免受神经细胞死亡的影响。

  公开号：

  US09095571B2

文献信息

• PRO-NEUROGENIC COMPOUNDS
  申请人：McKnight Steven L.

  公开号：US20120022096A1

  公开（公告）日：2012-01-26

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  该技术通常涉及化合物和方法，用于刺激神经发生（例如，产后神经发生，包括产后海马和下丘脑神经发生），和/或保护神经细胞免受细胞死亡的影响。本文披露了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病（如精神分裂症、重度抑郁症、躁郁症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、周围神经损伤、与各种情况相关的生理性体重减轻，以及与正常衰老、化疗等相关的认知衰退方面具有治疗益处。
• Pro-Neurogenic Compounds
  申请人：McKnight Steven L.

  公开号：US20130040977A1

  公开（公告）日：2013-02-14

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  该技术通常涉及化合物和方法，用于刺激神经发生（例如，产后神经发生，包括产后海马和下丘脑神经发生）和/或保护神经细胞免受细胞死亡的影响。本文披露了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病的治疗方面具有治疗益处，例如精神分裂症、重度抑郁症、躁狂症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩性侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、周围神经损伤、与各种情况相关的生理性减重，以及与正常衰老、化疗等相关的认知衰退。
• Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds
  申请人：UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS OF THE

  公开号：US20130184271A1

  公开（公告）日：2013-07-18

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  本技术通常涉及化合物和方法，用于刺激神经发生新生（例如，出生后神经发生新生，包括出生后海马和下丘脑神经发生新生）和/或保护神经细胞免受细胞死亡。本文介绍了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病（如精神分裂症、重度抑郁症、躁郁症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩性侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、外周神经损伤、与各种疾病相关的生理性体重下降以及与正常衰老、化疗等相关的认知衰退中具有治疗益处。
• Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds
  申请人：Board of Regents of the University of Texas System

  公开号：US20130184300A1

  公开（公告）日：2013-07-18

  This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.

  本发明通常涉及刺激神经发生（例如，产后神经发生，例如，产后海马神经发生）和保护神经细胞免受死亡的影响。
• Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds
  申请人：Board of Regents of the University of Texas System

  公开号：US20130184301A1

  公开（公告）日：2013-07-18

  This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.

  本发明通常涉及刺激神经发生（例如，产后神经发生，例如产后海马神经发生）和保护神经细胞免受死亡的方法。